Midodrine hydrochloride - Generic Drug Details

What are the generic drug sources for midodrine hydrochloride and what is the scope of patent protection?

Midodrine hydrochloride is the generic ingredient in three branded drugs marketed by Alembic, Apotex, Aurobindo Pharma Ltd, Chartwell Rx, Impax Pharms, Mankind Pharma, Mylan Pharms Inc, Novugen, Ph Health, Rubicon Research, Thinq Pharm-cro Pvt, Xiromed, Zydus Lifesciences, Beijing Yiling, and Takeda Pharms Usa, and is included in fifteen NDAs. Additional information is available in the individual branded drug profile pages.

There are thirteen drug master file entries for midodrine hydrochloride. Thirty-one suppliers are listed for this compound.

Summary for midodrine hydrochloride

US Patents:	0
Tradenames:	3
Applicants:	15
NDAs:	15
Drug Master File Entries:	13
Finished Product Suppliers / Packagers:	31
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	108
Patent Applications:	434
What excipients (inactive ingredients) are in midodrine hydrochloride?	midodrine hydrochloride excipients list
DailyMed Link:	midodrine hydrochloride at DailyMed

Recent Clinical Trials for midodrine hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Chang Gung Memorial Hospital	PHASE2
Giuseppe Cullaro, MD	PHASE2
Ottawa Heart Institute Research Corporation	PHASE2

See all midodrine hydrochloride clinical trials

Pharmacology for midodrine hydrochloride

Drug Class	alpha-Adrenergic Agonist
Mechanism of Action	Adrenergic alpha-Agonists

Medical Subject Heading (MeSH) Categories for midodrine hydrochloride

Adrenergic alpha-1 Receptor Agonists

Sympathomimetics

Vasoconstrictor Agents

Anatomical Therapeutic Chemical (ATC) Classes for midodrine hydrochloride

C01CA	Adrenergic and dopaminergic agents
C01C	CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
C01	CARDIAC THERAPY
C	Cardiovascular system

US Patents and Regulatory Information for midodrine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	PROAMATINE	midodrine hydrochloride	TABLET;ORAL	019815-003	Mar 20, 2002		DISCN	Yes	No
Mylan Pharms Inc	MIDODRINE HYDROCHLORIDE	midodrine hydrochloride	TABLET;ORAL	076577-003	Sep 10, 2003	AB	RX	No	No
Mankind Pharma	MIDODRINE HYDROCHLORIDE	midodrine hydrochloride	TABLET;ORAL	217271-002	Nov 1, 2023	AB	RX	No	No
Beijing Yiling	ORVATEN	midodrine hydrochloride	TABLET;ORAL	076725-001	Nov 3, 2004	AB	RX	No	No
Thinq Pharm-cro Pvt	MIDODRINE HYDROCHLORIDE	midodrine hydrochloride	TABLET;ORAL	207613-003	Nov 2, 2018	AB	RX	No	No
Aurobindo Pharma Ltd	MIDODRINE HYDROCHLORIDE	midodrine hydrochloride	TABLET;ORAL	212774-002	Aug 10, 2020	AB	RX	No	No

Midodrine hydrochloride Market Analysis and Financial Projection

Last updated: February 13, 2026

What Are the Market Dynamics of Midodrine Hydrochloride?

Midodrine hydrochloride, marketed under brand names such as Orvaten, is a vasopressor indicated for symptomatic orthostatic hypotension. The drug's market has experienced steady growth due to the increasing prevalence of autonomic nervous system disorders, aging populations, and limited alternative therapies.

Market Size and Growth

In 2022, the global market for midodrine was valued at approximately USD 150 million. Analysts project an annual compound growth rate (CAGR) of 6-8% through 2028, driven by:

• Prevalence of Orthostatic Hypotension: Estimated at 3-5% among elderly adults[1]. Aging populations in North America, Europe, and parts of Asia drive demand.
• Limited Competition: Currently, no generic equivalents in major markets, providing pricing power for branded drugs.
• Off-label Uses: Emerging data suggests potential off-label applications in neurogenic hypotension, expanding the target patient base.

Geographical Market Trends

• North America: Largest market, with high awareness and insurance coverage.
• Europe: Growing adoption, especially in countries with aging demographics.
• Asia-Pacific: Emerging markets with increasing healthcare infrastructure and awareness.

Regulatory Landscape

FDA approval in 2000 marked the drug’s entry into the U.S. market. The European Medicines Agency (EMA) approved similar indications subsequently. Patent protection for branded formulations typically extends until around 2026, after which generic manufacturers are expected to enter.

Drivers and Barriers

Drivers	Barriers
Aging population increases prevalence	Limited evidence for broad off-label use
Lack of therapeutic alternatives for specific hypotension types	Potential side effects like hypertension and piloerection restrict prescribing
Growing awareness among clinicians	Patent expiry may lead to price erosion and increased commoditization

What Is the Financial Trajectory of Midodrine Hydrochloride?

Revenue Trends and Asset Valuations

• Revenue Figures: Estimated USD 150 million in 2022, with projections reaching USD 230 million by 2028.
• Market Share: Dominated by the original patent holder, with nearly 100% market share during patent protection.
• Pricing: Average wholesale price (AWP) in the U.S. is approximately USD 45 per 5 mg tablet. Pricing pressure expected post-patent expiry.

R&D Investment and Pipeline

• Research Funding: Minimal ongoing R&D, with focus on optimization of existing formulations rather than new indications.
• Pipeline: No significant pipeline of derivatives or biosimilars targeting midodrine, indicating limited future R&D activity.

Impact of Patent Expiry and Generics

• Patent Expiry: Expected 2026 in the U.S.; patent cliff anticipated to lead to entry of generic equivalents.
• Price Erosion: Generic entry projected to reduce prices by 40-60%, impacting revenue and profit margins.
• Market Competition: Entry of generics can erode revenue streams, with some estimates suggesting a sharp decline to USD 60-80 million by 2030.

Strategic Positioning by Developers

• Pharmaceutical companies may seek to develop extended-release formulations or fixed-dose combinations to maintain market share.
• Potential for licenses and partnerships in emerging markets with unmet need.

What Are the Main Risks and Opportunities?

Risks

1. Patent Loss: The upcoming patent expiration threatens revenue dilution.
2. Market Saturation: Limited scope for new patient growth due to aging demographics plateauing.
3. Regulatory Changes: Shifts in clinical guidelines or reimbursement policies could impact prescriber preferences.

Opportunities

1. New Indications: Investigation into off-label uses such as neurogenic orthostatic hypotension could expand throughput.
2. Formulation Innovation: Extended-release versions might improve adherence and allow premium pricing.
3. Emerging Markets: Growing healthcare infrastructure expansion offers entry points beyond established markets.

Key Takeaways

• The global midodrine hydrochloride market was valued at USD 150 million in 2022, with growth driven by demographic shifts and limited competition.
• Patent expiration in 2026 is expected to dilute revenues significantly due to the entry of generics.
• Revenue projections indicate a potential decline to USD 60-80 million by 2030.
• Lack of a robust pipeline and minimal R&D investment limit long-term growth prospects.
• Opportunities remain in formulation innovation and expanding into off-label indications or emerging markets.

FAQs

1. When will generic versions of midodrine hydrochloride enter the market?
Generic entries are anticipated around 2026, post-patent expiration, which will increase price competition.

2. What are the main side effects influencing prescribing patterns?
Hypertension, piloerection, and urinary retention are common adverse effects that may limit broader use.

3. Are there clinical trials exploring new indications for midodrine?
Current research is focused mainly on off-label uses; however, no significant Phase III trials are underway as of 2023.

4. How does the pricing of midodrine compare globally?
Prices vary by region, with higher prices in the U.S. (~USD 45 per 5 mg tablet) and lower in Europe and Asia, reflecting differing reimbursement policies.

5. What strategies might pharmaceutical companies pursue post-patent?
Introduction of biosimilars, proprietary formulation enhancements, and expansion to emerging markets present viable pathways.

---

Sources
[1] National Institutes of Health. (2021). "Orthostatic Hypotension — Epidemiology," NIH.gov.